Coverage at a glance
| Indication | Coverage |
|---|---|
| Obesity / chronic weight management | Covered with prior authorization |
| Obstructive sleep apnea (SURMOUNT-OSA indication) | Covered with prior authorization |
If your plan denies coverage, two cash programs to check.
- Strut Health$149 a month, with auto-refillcompounded semaglutide, not FDA-approvedCheck price →
- Shed$199 a monthcompounded semaglutide, not FDA-approvedCheck price →
Prior authorization: the plan reviews the prescription before it pays.
Yes, once the plan signs off. Highmark's commercial and ACA plans cover Zepbound and Wegovy for weight management under policy J-1388. Zepbound is the one the plan prefers. Highmark's own rule is tighter than the drug label. It requires a starting BMI of 40 or higher, plus a qualifying weight-related condition. The label sets the bar at BMI 30. A self-funded employer can still carve the benefit out, so check that your plan has it before you submit. This answer covers Commercial fully insured and ACA.
Source: Highmark policy J-1388. Checked August 26, 2026.
What it costs once they say yes. With commercial insurance the manufacturer savings card takes Zepbound or Wegovy to as little as $25 a month. Your plan sets the copay before the card applies. What Zepbound costs with your plan. What Wegovy costs with your plan.
This varies by plan. Highmark covers these drugs under its commercial and ACA pharmacy policy. A self-funded employer can still carve weight-loss drugs out. Check that your plan has the benefit before you submit. Express Scripts runs the drug benefit for most Highmark commercial plans. Highmark Medicare Advantage follows CMS rules, so weight loss on its own is not covered there. A member needs the cardiovascular route or the sleep-apnea route instead.
Coverage by indication
| BMI threshold | A starting BMI of 40 or higher, plus a qualifying weight-related condition. This is Highmark's own rule. It is tighter than the drug label, which sets the bar at BMI 30, or 27 with a weight-related condition |
| Step therapy | Six months of diet and physical activity on the record before you start, kept up while you are on the drug. Zepbound is the drug the plan prefers. So a request for Wegovy, Saxenda or Foundayo has to show that Zepbound is not safe for you, or that you could not tolerate it. |
What the prior authorization needs:
- Baseline height, weight, and BMI documentation showing BMI 40 or higher
- One qualifying route on top of the BMI 40. That can be prediabetes plus high triglycerides plus low HDL, all three together. It can be one condition caused by obesity, such as coronary artery disease or moderate to severe sleep apnea. Or it can be at least two conditions from a longer list, which includes hypertension, PCOS and severe knee or hip pain
- Six months of diet and physical activity documented before initiation
- The plan has to sign off. The member must not have type 2 diabetes, and must not be taking another GLP-1
Source: Highmark policy J-1388. Highmark's own policy PDF J-1388-028, in force from 07/01/2026.
Policy J-1388 keeps a Zepbound route for sleep apnea on its own. It asks for a BMI of 30 or higher, a sleep specialist, and an AHI of 15 or higher. That route runs only on Delaware commercial and ACA plans that do not carry the obesity benefit. For every other Highmark member, sleep apnea that is moderate to severe counts instead as one qualifying condition under the BMI 40 route above.
| BMI threshold | BMI 30 or higher. This is the sleep-apnea route on its own, and it runs only on Delaware plans with no obesity benefit |
| Sleep study (AHI) | Obstructive sleep apnea that is moderate to severe. That means an apnea-hypopnea index of 15 or higher on a baseline sleep study taken without PAP |
What the prior authorization needs:
- Prescribed by or in consultation with a sleep specialist
- Moderate to severe OSA diagnosis with baseline AHI of 15 or higher documented
- You are using PAP as prescribed, or there is a record that it failed you, that you could not tolerate it, or that it is not safe for you
- To renew it you have to show the AHI came down from where it started
Source: Highmark Pharmacy Policy J-1388 Anti-Obesity (Enhanced), Commercial and Healthcare Reform. Highmark's own policy PDF J-1388-028, Section VI, in force from 07/01/2026.
Ozempic, Mounjaro and Rybelsus on Highmark plans
Ozempic, Mounjaro and Rybelsus are approved for type 2 diabetes, not weight loss.
Does Highmark cover Ozempic?
Yes, with prior approval. Highmark pays for Ozempic once your prescriber gets the plan to sign off.
Highmark covers Ozempic for type 2 diabetes on its commercial drug lists. It usually sits at Tier 2, the plan has to sign off, and a quantity limit applies. Ozempic is not covered for weight loss, because the FDA approved it for type 2 diabetes only. Wegovy is the semaglutide Highmark covers for weight loss. That one runs under a separate weight-loss drug policy, and a self-insured employer can turn it down.
Checked August 27, 2026.
What Highmark requires for Ozempic
| Step therapy | Not required |
What the prior authorization needs:
- Confirmed type 2 diabetes diagnosis
- Prior authorization required. Highmark drug lists flag Ozempic with a PA marker.
- Quantity limits apply.
- The plan usually asks for the A1C and a record of earlier therapy at sign-off.
- The rules differ by Highmark commercial drug list, such as Comprehensive, National Select and Core. Some lists ask you to try a preferred drug first, instead of a sign-off or alongside it.
Source: Highmark Comprehensive Formulary (commercial drug list search). The plan's own covered-drug list. Lower confidence: the policy file would not open at the payer's own address, so the policy number and rules were checked against a second source.
Does Highmark cover Mounjaro?
Yes, with prior approval. Highmark pays for Mounjaro once your prescriber gets the plan to sign off.
Highmark covers Mounjaro for type 2 diabetes on its commercial and ACA (Healthcare Reform) plans, under pharmacy policy J-1300. Mounjaro is tirzepatide. The policy names one thing to prove: a type 2 diabetes diagnosis on the record, ICD-10 E11. A member with a claim for another diabetes drug in the past 720 days is approved at the pharmacy counter, with no sign-off at all. Highmark does not cover Mounjaro for weight loss, and will not approve it for obesity on its own. Zepbound is the tirzepatide the FDA approved for weight loss, and it sits under a separate Highmark weight-loss policy.
Checked August 27, 2026.
What Highmark requires for Mounjaro
| Step therapy | Not required |
What the prior authorization needs:
- A type 2 diabetes diagnosis on the record, ICD-10 E11. That is the only approval criterion in the policy.
- A member with a claim in the past 720 days for one diabetes drug that is not a GLP-1 is approved at the pharmacy counter, with no sign-off. Metformin, an SGLT2 inhibitor and insulin are examples.
- The policy sets no A1C bar, and it does not make you fail another drug first.
- Approvals last up to 12 months.
- Not approved for obesity on its own. Zepbound is the tirzepatide for weight loss, and it runs under a separate weight-loss policy.
Source: Highmark policy J-1300. The plan's own coverage policy.
Does Highmark cover Rybelsus?
Yes, with prior approval. Highmark pays for Rybelsus once your prescriber gets the plan to sign off.
Highmark covers Rybelsus for type 2 diabetes under pharmacy policy J-1300. The sign-off clears on its own at the pharmacy counter for a member with two things on file. One is a type 2 diabetes diagnosis, ICD-10 E11. The other is a pharmacy claim in the past 720 days for another diabetes drug that is not a GLP-1. A member without that recent history needs a standard sign-off. Rybelsus is not covered for weight loss. The FDA approved it for type 2 diabetes only, and Highmark will not approve it for obesity on its own. Wegovy is the semaglutide for weight loss, and Highmark reviews it under a separate weight-loss policy.
Checked August 28, 2026.
What Highmark requires for Rybelsus
| Step therapy | Not required |
What the prior authorization needs:
- Documented diagnosis of type 2 diabetes (ICD-10 E11).
- The sign-off clears on its own at the pharmacy counter, if the member has a claim in the past 720 days for one diabetes drug that is not a GLP-1. Metformin, a sulfonylurea, an SGLT2 inhibitor and insulin are examples. A member without that history needs a standard sign-off.
- Rybelsus is a preferred GLP-1 on this policy, so you do not have to step through a second GLP-1.
- Not approved for a sole diagnosis of obesity.
Source: Highmark policy J-1300. The plan's own coverage policy.
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list then have your prescriber submit it. Plans that approve reassess at renewal, so know your long-term maintenance dose before you start.
- Start with the Highmark prior-authorization letter template, which cites this plan's policy and the diagnosis codes a reviewer looks for. Pick the indication that matches your clinical picture.
- Read why plans say no and the four ways to appeal in the GLP-1 insurance guide.
- Your plan may treat another GLP-1 differently. The Highmark coverage check lists all 4, with the source for each.
- If the plan denies it, the appeal letter library has a template for each reason a plan gives. That covers the peer-to-peer call with a plan doctor, the Level 1 and Level 2 appeals inside the plan, and the outside review that follows them.
- Call the number on your insurance card and ask whether your specific plan includes the weight-management drug benefit before you submit.
- If your plan does not cover the indication you need, compare cash prices in the cost guide or check whether a clinical trial near you fits. Neither one goes through your insurer. Clinical trials cost nothing and many pay you for your time.
What it costs without insurance
The programs below bill you directly. Prices checked every Monday.
Frequently asked questions
Does Highmark cover Zepbound and Wegovy for weight loss?
Yes, once the plan signs off. Highmark's commercial and ACA plans cover Zepbound and Wegovy for weight management under policy J-1388. Zepbound is the one the plan prefers. Highmark's own rule is tighter than the drug label. It requires a starting BMI of 40 or higher, plus a qualifying weight-related condition. The label sets the bar at BMI 30. A self-funded employer can still carve the benefit out, so check that your plan has it before you submit. Policy checked August 2026.
What does Highmark require to approve Zepbound and Wegovy for weight loss?
For obesity / chronic weight management: The BMI requirement is a starting BMI of 40 or higher, plus a qualifying weight-related condition. This is Highmark's own rule. It is tighter than the drug label, which sets the bar at BMI 30, or 27 with a weight-related condition. Six months of diet and physical activity on the record before you start, kept up while you are on the drug. Zepbound is the drug the plan prefers. So a request for Wegovy, Saxenda or Foundayo has to show that Zepbound is not safe for you, or that you could not tolerate it.
Why might Highmark deny Zepbound and Wegovy for weight loss even if I meet the criteria?
Highmark covers these drugs under its commercial and ACA pharmacy policy. A self-funded employer can still carve weight-loss drugs out. Check that your plan has the benefit before you submit. Express Scripts runs the drug benefit for most Highmark commercial plans. Highmark Medicare Advantage follows CMS rules, so weight loss on its own is not covered there. A member needs the cardiovascular route or the sleep-apnea route instead.
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Every page here comes from the payer's own policy, a federal law, or KFF's plan research. Each row links its source and gives the date we read it. Some plan files load at the address the payer gives but will not open. We check those against a second source and mark the row lower confidence. Job-based plans also choose whether to add the weight-drug benefit at all, so those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.
